Cargando…
Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2
SARS-CoV-2 (CoV-2) viral infection results in COVID-19 disease, which has caused significant morbidity and mortality worldwide. A vaccine is crucial to curtail the spread of SARS-CoV-2, while therapeutics will be required to treat ongoing and reemerging infections of SARS-CoV-2 and COVID-19 disease....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806709/ https://www.ncbi.nlm.nih.gov/pubmed/35127966 http://dx.doi.org/10.1016/j.omtm.2022.01.015 |
_version_ | 1784643517780328448 |
---|---|
author | Scott, Tristan A. Supramaniam, Aroon Idris, Adi Cardoso, Angelo A. Shrivastava, Surya Kelly, Gabrielle Grepo, Nicole A. Soemardy, Citradewi Ray, Roslyn M. McMillan, Nigel A.J. Morris, Kevin V. |
author_facet | Scott, Tristan A. Supramaniam, Aroon Idris, Adi Cardoso, Angelo A. Shrivastava, Surya Kelly, Gabrielle Grepo, Nicole A. Soemardy, Citradewi Ray, Roslyn M. McMillan, Nigel A.J. Morris, Kevin V. |
author_sort | Scott, Tristan A. |
collection | PubMed |
description | SARS-CoV-2 (CoV-2) viral infection results in COVID-19 disease, which has caused significant morbidity and mortality worldwide. A vaccine is crucial to curtail the spread of SARS-CoV-2, while therapeutics will be required to treat ongoing and reemerging infections of SARS-CoV-2 and COVID-19 disease. There are currently no commercially available effective anti-viral therapies for COVID-19, urging the development of novel modalities. Here, we describe a molecular therapy specifically targeted to neutralize SARS-CoV-2, which consists of extracellular vesicles (EVs) containing a novel fusion tetraspanin protein, CD63, embedded within an anti-CoV-2 nanobody. These anti-CoV-2-enriched EVs bind SARS-CoV-2 spike protein at the receptor-binding domain (RBD) site and can functionally neutralize SARS-CoV-2. This work demonstrates an innovative EV-targeting platform that can be employed to target and inhibit the early stages of SARS-CoV-2 infection. |
format | Online Article Text |
id | pubmed-8806709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-88067092022-02-02 Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2 Scott, Tristan A. Supramaniam, Aroon Idris, Adi Cardoso, Angelo A. Shrivastava, Surya Kelly, Gabrielle Grepo, Nicole A. Soemardy, Citradewi Ray, Roslyn M. McMillan, Nigel A.J. Morris, Kevin V. Mol Ther Methods Clin Dev Original Article SARS-CoV-2 (CoV-2) viral infection results in COVID-19 disease, which has caused significant morbidity and mortality worldwide. A vaccine is crucial to curtail the spread of SARS-CoV-2, while therapeutics will be required to treat ongoing and reemerging infections of SARS-CoV-2 and COVID-19 disease. There are currently no commercially available effective anti-viral therapies for COVID-19, urging the development of novel modalities. Here, we describe a molecular therapy specifically targeted to neutralize SARS-CoV-2, which consists of extracellular vesicles (EVs) containing a novel fusion tetraspanin protein, CD63, embedded within an anti-CoV-2 nanobody. These anti-CoV-2-enriched EVs bind SARS-CoV-2 spike protein at the receptor-binding domain (RBD) site and can functionally neutralize SARS-CoV-2. This work demonstrates an innovative EV-targeting platform that can be employed to target and inhibit the early stages of SARS-CoV-2 infection. American Society of Gene & Cell Therapy 2022-02-02 /pmc/articles/PMC8806709/ /pubmed/35127966 http://dx.doi.org/10.1016/j.omtm.2022.01.015 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Scott, Tristan A. Supramaniam, Aroon Idris, Adi Cardoso, Angelo A. Shrivastava, Surya Kelly, Gabrielle Grepo, Nicole A. Soemardy, Citradewi Ray, Roslyn M. McMillan, Nigel A.J. Morris, Kevin V. Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2 |
title | Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2 |
title_full | Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2 |
title_fullStr | Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2 |
title_full_unstemmed | Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2 |
title_short | Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2 |
title_sort | engineered extracellular vesicles directed to the spike protein inhibit sars-cov-2 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806709/ https://www.ncbi.nlm.nih.gov/pubmed/35127966 http://dx.doi.org/10.1016/j.omtm.2022.01.015 |
work_keys_str_mv | AT scotttristana engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 AT supramaniamaroon engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 AT idrisadi engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 AT cardosoangeloa engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 AT shrivastavasurya engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 AT kellygabrielle engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 AT greponicolea engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 AT soemardycitradewi engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 AT rayroslynm engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 AT mcmillannigelaj engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 AT morriskevinv engineeredextracellularvesiclesdirectedtothespikeproteininhibitsarscov2 |